Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Dermata Therapeutics, Inc. (DRMA : NSDQ)

• Company Description    Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $0.66 Daily Weekly Monthly 20 Day Moving Average: 79,604 shares Shares Outstanding: 6.38 (millions) Market Capitalization: $4.24 (millions) Beta: 0.54 52 Week High: $3.79 52 Week Low: $0.57 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.68% -10.79% 12 Week -15.74% -29.31% Year To Date -50.81% -53.93%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3525 DEL MAR HEIGHTS ROAD SUITE 322 - SAN DIEGO,CA 92130 USA ph: 858-800-2543 fax: - sproehl@dermatarx.com http://www.dermatarx.com

• General Corporate Information    Officers Gerald T. Proehl - President; Chief Executive Officer and Chairman Kyri K. Van Hoose - Chief Financial Officer Wendell Wierenga - Director Mary Fisher - Director Steven J. Mento - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 249845405 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/06/25 Share - Related Items Shares Outstanding: 6.38 Most Recent Split Date: 5.00 (0.07:1) Beta: 0.54 Market Capitalization: $4.24 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.55 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 93.61% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -270.81 12/31/24 - -366.01 ROA 06/30/25 - - 03/31/25 - -179.96 12/31/24 - -238.14 Current Ratio 06/30/25 - - 03/31/25 - 3.70 12/31/24 - 1.79 Quick Ratio 06/30/25 - - 03/31/25 - 3.70 12/31/24 - 1.79 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 1.21 12/31/24 - 0.62 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©